Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Trial status:Recruitment Complete
Study Identifier:
MV-0715-CP-001.01
ClinicalTrials.gov Identifier:
NCT02672917
EudraCT Identifier:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech Research & Development, Inc.
Recruitment Complete

Trial details

Medical Condition
  • Pancreatic Cancer
    • Study Drug
  • Drug: MVT-5873
  • Drug: modified FOLFIRINOX (mFOLFIRINOX)
  • Drug: gemcitabine + nab-paclitaxel
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18+
    Estimated Trial Date
    Jan 2016 - Aug 2024

    Protocol summary

    Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies.

    Trial locations

    Location
    Status
    Location
    HonorHealth Research Institute
    Scottsdale, Arizona, United States, 85258
    Status
    Location
    The Angeles Clinic & Research Institute
    Los Angeles, California, United States, 90025
    Status
    Location
    Florida Cancer Specialist and Research Institute
    Sarasota, Florida, United States, 34233
    Status
    Location
    MSKCC
    New York, New York, United States, 10065
    Status
    Location
    Sarah Cannon Research Institute
    Nashville, Tennessee, United States, 37203
    Status